Founded in 2010 and headquartered in Cambridge, Massachusetts, Vedanta Biosciences develops immunotherapies to treat immune-mediated and infectious diseases. The company uses a discovery platform to identify bacteria with drug-like properties and create optimized therapeutic consortia. With funding from investors including the Bill & Melinda Gates Foundation and Bristol-Myers Squibb, Vedanta plans to advance its product candidates derived from the microbiome and accelerate the development of its product pipeline.